Show simple item record

dc.contributor.authorKim, Yunjeong
dc.contributor.authorLiu, Hongwei
dc.contributor.authorKankanamalage, Anushka C. Galasiti
dc.contributor.authorWeerasekara, Sahani
dc.contributor.authorHua, Duy H.
dc.contributor.authorGroutas, William C.
dc.contributor.authorChang, Kyeong-Ok
dc.contributor.authorPedersen, Niels C.
dc.date.accessioned2016-08-01T00:26:22Z
dc.date.available2016-08-01T00:26:22Z
dc.date.issued2016-03-30
dc.identifier.citationKim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, et al. (2016) Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog 12(3): e1005531en_US
dc.identifier.issn1553-7366
dc.identifier.otherWOS:000378154800043
dc.identifier.urihttp://dx.doi.org/10.1371/journal.ppat.1005531
dc.identifier.urihttp://hdl.handle.net/10057/12300
dc.descriptionThis is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.descriptionCorrection: There are errors in the Funding section. The correct funding information is as follows: The in vitro assays and drug synthesis were supported by NIH grant R01AI109039 (http://www.nih.gov, PI: KC) and Morris Animal Foundation D14FE-012 (http://www.morrisanimalfoundation.org, PI: YK). The PK and safety studies were supported by Winn Feline Foundation Miller Fund MT13-006 (http://www.winnfelinefoundation.org. PI: NCP) and the Center for Companion Animal Health (http://www.vetmed.ucdavis.edu/ccah/. PI: NCP). The in vivo efficacy study was supported by the Center for Companion Animal Health (http://www.vetmed.ucdavis.edu/ccah/. PI: NCP) and the Kansas State University Global Food Systems program (GPRE002839) (PI: YK). Publication of this article was funded in part by the Kansas State University Open Access Publishing Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.description.abstractCoronaviruses infect animals and humans causing a wide range of diseases. The diversity of coronaviruses in many mammalian species is contributed by relatively high mutation and recombination rates during replication. This dynamic nature of coronaviruses may facilitate cross-species transmission and shifts in tissue or cell tropism in a host, resulting in substantial change in virulence. Feline enteric coronavirus (FECV) causes inapparent or mild enteritis in cats, but a highly fatal disease, called feline infectious peritonitis (FIP), can arise through mutation of FECV to FIP virus (FIPV). The pathogenesis of FIP is intimately associated with immune responses and involves depletion of T cells, features shared by some other coronaviruses like Severe Acute Respiratory Syndrome Coronavirus. The increasing risks of highly virulent coronavirus infections in humans or animals call for effective antiviral drugs, but no such measures are yet available. Previously, we have reported the inhibitors that target 3C-like protease (3CLpro) with broad-spectrum activity against important human and animal coronaviruses. Here, we evaluated the therapeutic efficacy of our 3CLpro inhibitor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated. Antiviral treatment was associated with a rapid improvement in fever, ascites, lymphopenia and gross signs of illness and cats returned to normal health within 20 days or less of treatment. Significant reduction in viral titers was also observed in cats. These results indicate that continuous virus replication is required for progression of immune-mediated inflammatory disease of FIP. These findings may provide important insights into devising therapeutic strategies and selection of antiviral compounds for further development for important coronaviruses in animals and humans.en_US
dc.description.sponsorshipNIH grant R01AI109039 (http://www.nih.gov, PI: KC) and Morris Animal Foundation M13-006 (http://www.morrisanimalfoundation.org, PI: YK). The PK and safety studies were supported by Winn Feline Foundation Miller Fund MT13-006 (http://www.winnfelinefoundation.org. PI: NCP). The in vivo efficacy study was supported by the Kansas State University Global Food Systems program (GPRE002839) (PI: YK). Publication of this article was funded in part by the Kansas State University Open Access Publishing Fund.en_US
dc.language.isoen_USen_US
dc.publisherPublic Library of Science Pathogensen_US
dc.relation.ispartofseriesPLOS Pathogens;v.12:no.3
dc.rightsOpen Access
dc.subjectPeritonitis virus-infectionen_US
dc.subjectQuality-of-lifeen_US
dc.subjectFeline-coronavirusen_US
dc.subject3c-like proteaseen_US
dc.subjectNatural-resistanceen_US
dc.subjectSurvival-timeen_US
dc.subjectMain proteaseen_US
dc.subjectTNF-alphaen_US
dc.subjectSARSen_US
dc.subjectDesignen_US
dc.titleReversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitoren_US
dc.typeArticleen_US
dc.rights.holderCopyright: © 2016 Kim et al.en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record